phosphatidylcholines has been researched along with darapladib in 1 studies
| Studies (phosphatidylcholines) | Trials (phosphatidylcholines) | Recent Studies (post-2010) (phosphatidylcholines) | Studies (darapladib) | Trials (darapladib) | Recent Studies (post-2010) (darapladib) |
|---|---|---|---|---|---|
| 32,204 | 443 | 5,593 | 104 | 28 | 81 |
| Protein | Taxonomy | phosphatidylcholines (IC50) | darapladib (IC50) |
|---|---|---|---|
| Platelet-activating factor acetylhydrolase | Homo sapiens (human) | 0.0003 | |
| Platelet-activating factor acetylhydrolase | Mus musculus (house mouse) | 0.0003 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bollinger, JG; Burgert, ME; Fenning, RS; Gelb, MH; Hamamdzic, D; Hoffman, BE; Li, J; Macphee, CH; Mirabile, RC; Mohler, ER; Pelchovitz, DJ; Postle, A; Shi, Y; Walker, MC; Webb, CL; Wilensky, RL; Yang, J; Zalewski, A; Zhang, L; Zhang, P | 1 |
1 other study(ies) available for phosphatidylcholines and darapladib
| Article | Year |
|---|---|
Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Animals; Benzaldehydes; Coronary Artery Disease; Coronary Vessels; Enzyme Inhibitors; Gene Expression; Male; Oximes; Phosphatidylcholines; Swine | 2008 |